MolecuLight and its Taiwanese distributor, Healtdeva, are highlighting published research showing the efficacy of MolecuLight's i:X device on managing deep sternal wound infections.
The study, published in the Journal of Wound Care and based in Taiwan, found that using MolecuLight's real-time fluorescence imaging in treatment protocols for these infections led to reduced antibiotic use and associated costs. It also led to lower complications compared with the standard of care.
Specifically, the i:X device's use increased the likelihood of white blood cell counts returning to normal within seven days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by sevenfold (78.8% vs. 31.8%) compared with hyperbaric oxygen energy.
And patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days), the company said.
